Latest data from May 6, 2022
Number of Health Center respondents = 31 (84% of all Health Centers)
Data represents information provided by health centers from a single, specified reporting date. Summary information across report dates is not comparable due to differences in which health centers responded for a given report date.
Patients Tested
| Metrics | Value |
|---|---|
| Patients Tested for COVID-19, Virus Detection (PCR, Antigen)1 | 8,023 |
| Racial and/or Ethnic Minority Patients Tested for COVID-19, Virus Detection (PCR, Antigen) | 76.42% |
| Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen)1 | 914 |
| Racial and/or Ethnic Minority Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen) | 69.97% |
Patients by Race and Ethnicity
| Race/Ethnicity | Patients Tested, Virus Detection (PCR, Antigen)2 | Patients Tested Positive, Virus Detection (PCR, Antigen)2 |
|---|---|---|
| White, Non-Hispanic/Latino Patients | 20.70% | 26.15% |
| White, Hispanic/Latino Patients | 28.56% | 20.02% |
| Black/African American, Non-Hispanic/Latino Patients | 12.88% | 16.52% |
| Black/African American, Hispanic/Latino Patients | 5.95% | 6.02% |
| Asian Patients3 | 4.51% | 6.35% |
| American Indian/Alaska Native Patients3 | 0.44% | 0.44% |
| Native Hawaiian/Other Pacific Islander Patients3 | 1.05% | 0.44% |
| Patients with More Than One Race3 | 3.25% | 2.41% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 10.46% | 8.75% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 5.20% | 5.80% |
| Unreported/Refused to Report Race and Ethnicity | 7.02% | 7.11% |
Patients Vaccinated
| Metrics | Value |
|---|---|
| COVID-19 Immunization Series Initiated | 847 |
| Racial and/or Ethnic Minority Patients Who Initiated COVID-19 Immunization | 73.23% |
| COVID-19 Immunization Series Completed | 803 |
| Racial and/or Ethnic Minority Patients Who Completed COVID-19 Immunization | 81.72% |
| COVID-19 Immunization Series Additional | 2,676 |
| Racial and/or Ethnic Minority Patients Who Received an Additional Dose of COVID-19 Vaccine | 64.51% |
Vaccinations by Race and Ethnicity
| Race/Ethnicity | Patient COVID-19 Immunization Series Initiated2 | Patient COVID-19 Immunization Series Completed2 | Patient COVID-19 Immunization Series Additional2 |
|---|---|---|---|
| White, Non-Hispanic/Latino Patients | 22.79% | 16.19% | 32.96% |
| White, Hispanic/Latino Patients | 17.59% | 23.16% | 13.34% |
| Black/African American, Non-Hispanic/Latino Patients | 18.18% | 21.79% | 19.77% |
| Black/African American, Hispanic/Latino Patients | 5.31% | 5.35% | 7.17% |
| Asian Patients3 | 3.42% | 3.61% | 7.70% |
| American Indian/Alaska Native Patients3 | 0.24% | 0.00% | 1.12% |
| Native Hawaiian/Other Pacific Islander Patients3 | 1.30% | 1.00% | 0.90% |
| Patients with More Than One Race3 | 5.79% | 6.48% | 4.41% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 10.51% | 10.96% | 5.49% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 5.55% | 4.61% | 2.39% |
| Unreported/Refused to Report Race and Ethnicity | 9.33% | 6.85% | 4.75% |
Testing Logistics
Average Turnaround Time for COVID-19 Test Results, Virus Detection (PCR, Antigen)
| Metrics | Value |
|---|---|
| Less Than 1 Hour | 6.45% |
| 1 to 24 Hours | 38.71% |
| More Than 24 Hours | 45.16% |
| N/A | 9.68% |
Vaccine Logistics
Challenges in Deploying the COVID Vaccine
| Metrics | Value |
|---|---|
| Financial reimbursement for costs associated with vaccine administration | 6.45% |
| Staffing to administer the vaccine | 22.58% |
| Vaccine confidence | 35.48% |
| Vaccine storage capacity | 3.23% |
| Vaccine supply | 6.45% |
| Other | 9.68% |
| None | 35.48% |
Operations and Staff
| Metrics | Value |
|---|---|
| COVID-19 Vaccine Doses Received Only From Health Center COVID-19 Vaccine Program | 16.13% |
| Average Percent of Health Center Visits Conducted Virtually | 21.94% |
Mobile Vans, Pop-Up Clinics, and School-Based Sites
| Metrics | Value |
|---|---|
| Percent of Health Centers Hosting Mobile Vans, Pop-Up, and/or School-Based Clinics | 32.26% |
| Number of Mobile Van Sites | 21 |
| Number of Pop-up Clinics | 5 |
| Number of School-Based Vaccination Sites | 13 |
| Number of Family Vaccination Clinics | 14 |
Monoclonal Antibody Therapy
Methods in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Direct provision of monoclonal antibody therapies | 6.45% |
| Refer patients to another organization that provides monoclonal antibody therapies | 51.61% |
| None | 41.94% |
Challenges in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Access to therapeutics | 16.13% |
| Patient awareness/education | 3.23% |
| Staffing capacity | 12.90% |
| Therapy administration/onsite logistics | 9.68% |
| Other | 9.68% |
| None | 58.06% |
Test Kit Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Distributed Test Kits Received through the HRSA COVID-19 Testing Supply Program | 17 |
| Number of Test Kits Distributed through the HRSA COVID-19 Testing Supply Program | 8,718 |
Test Kit Distribution Methods4
| Metrics | Value |
|---|---|
| Provided to Existing Health Center Patients | 88.24% |
| Provided to General Public Who Came to the Health Center | 58.82% |
| Provided at Special Vaccination Events (e.g., through mobile vans, pop-up clinics, school-based clinics, family vaccination clinics) | 23.53% |
| Provided at Other Community Events | 47.06% |
| Provided to migratory/seasonal agricultural workers directly or through partnerships with community organizations serving these individuals | 5.88% |
| Provided to individuals with limited English proficiency directly or through partnerships with community organizations serving these individuals | 35.29% |
| Provided to older adults and/or individuals with disabilities directly or through partnerships with community organizations serving these individuals | 35.29% |
| Provided to school-age children and/or their families directly or through partnerships with schools | 29.41% |
| Provided to individuals living in HUD-assisted housing and/or individuals experiencing homelessness directly or through partnerships with local housing authorities | 29.41% |
| Other | 11.76% |
N95 Mask Distribution
| Metrics | Value |
|---|---|
| Health Centers that Distributed N95 Masks Received through the HRSA Health Center COVID-19 N95 Mask Program | 9 |
| Number of N95 Masks Distributed through the HRSA Health Center COVID-19 N95 Mask Program | 3,973 |
N95 Mask Distribution Methods5
| Metrics | Value |
|---|---|
| Provided to Existing Health Center Patients | 100.00% |
| Provided to General Public Who Came to the Health Center | 66.67% |
| Provided at Special Vaccination Events (e.g., through mobile vans, pop-up clinics, school-based clinics, family vaccination clinics) | 33.33% |
| Provided at Other Community Events | 66.67% |
| Provided to migratory/seasonal agricultural workers directly or through partnerships with community organizations serving these individuals | 11.11% |
| Provided to individuals with limited English proficiency directly or through partnerships with community organizations serving these individuals | 44.44% |
| Provided to older adults and/or individuals with disabilities directly or through partnerships with community organizations serving these individuals | 44.44% |
| Provided to school-age children and/or their families directly or through partnerships with schools | 22.22% |
| Provided to individuals living in HUD-assisted housing and/or individuals experiencing homelessness directly or through partnerships with local housing authorities | 0.00% |
| Other | 0.00% |
Oral Antiviral Medication Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Provided COVID-19 Oral Antiviral Medication through the HRSA Health Center COVID-19 Therapeutics Program | 14 |
| Racial and/or Ethnic Minority Patients Who Received COVID-19 Oral Antiviral Medication | 47.27% |
Oral Antiviral Medication Distribution by Race and Ethnicity
| Race/Ethnicity | Value |
|---|---|
| White, Non-Hispanic/Latino Patients | 38.18% |
| White, Hispanic/Latino Patients | 15.45% |
| Black/African American, Non-Hispanic/Latino Patients | 7.73% |
| Black/African American, Hispanic/Latino Patients | 1.82% |
| Asian Patients3 | 2.27% |
| American Indian/Alaska Native Patients3 | 0.91% |
| Native Hawaiian/Other Pacific Islander Patients3 | 3.18% |
| Patients with More Than One Race3 | 1.82% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 14.09% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 10.00% |
| Unreported/Refused to Report Race and Ethnicity | 4.55% |
Oral Antiviral Medication Distribution by Population Type
| Metrics | Value |
|---|---|
| Migratory/Agricultural Workers | 0.00% |
| Patients Experiencing Homelessness | 0.91% |
| Patients Who Are Residents of Public Housing | 11.82% |
| Patients with Limited English Proficiency | 30.00% |
| Children Under 18 Years of Age | 1.82% |
1 The reported number of patients tested do not represent the same patients included in the reported number of patients tested positive due to a lag between the date the specimen is collected and the availability of test results. Positivity rates cannot be inferred by dividing patients tested positive by patients tested for this reason.
2 Percentages may not add to 100% due to rounding to the hundredths.
3 Includes Hispanic/Latino and Non-Hispanic/Latino.
4 Percentages are calculated using the number of health centers that have distributed test kits received through the HRSA COVID-19 Testing Supply Program as the denominator.
5 Percentages are calculated using the number of health centers that have distributed N95 masks received through the HRSA Health Center COVID-19 N95 Mask Program as the denominator.
Date Last Reviewed: